Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2006 1
2012 1
2013 2
2014 1
2018 1
2021 1
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Feagan BG, et al. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734. N Engl J Med. 2013. PMID: 23964932 Free article. Clinical Trial.
Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Sandborn WJ, et al. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739. N Engl J Med. 2013. PMID: 23964933 Free article. Clinical Trial.
A framework for individualized splice-switching oligonucleotide therapy.
Kim J, Woo S, de Gusmao CM, Zhao B, Chin DH, DiDonato RL, Nguyen MA, Nakayama T, Hu CA, Soucy A, Kuniholm A, Thornton JK, Riccardi O, Friedman DA, El Achkar CM, Dash Z, Cornelissen L, Donado C, Faour KNW, Bush LW, Suslovitch V, Lentucci C, Park PJ, Lee EA, Patterson A, Philippakis AA, Margus B, Berde CB, Yu TW. Kim J, et al. Among authors: margus b. Nature. 2023 Jul;619(7971):828-836. doi: 10.1038/s41586-023-06277-0. Epub 2023 Jul 12. Nature. 2023. PMID: 37438524 Free PMC article.
Drug repurposing screen for the rare disease ataxia-telangiectasia.
Jayanth N, Mahé G, Campbell M, Lipkin M, Jain S, van de Bospoort R, Thornton J, Margus B, Fischer DF. Jayanth N, et al. Among authors: margus b. SLAS Discov. 2024 Dec 4;30:100200. doi: 10.1016/j.slasd.2024.100200. Online ahead of print. SLAS Discov. 2024. PMID: 39638147 Free article.
Neurofilament light chain: A novel blood biomarker in patients with ataxia telangiectasia.
Veenhuis SJG, Gupta AS, de Gusmão CM, Thornton J, Margus B, Rothblum-Oviatt C, Otto M, Halbgebauer S, van Os NJH, van de Warrenburg BPC, Verbeek MM, Willemsen MAAP. Veenhuis SJG, et al. Among authors: margus b. Eur J Paediatr Neurol. 2021 May;32:93-97. doi: 10.1016/j.ejpn.2021.04.002. Epub 2021 Apr 9. Eur J Paediatr Neurol. 2021. PMID: 33878608 Free article.
Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.
Gross V, Bar-Meir S, Lavy A, Mickisch O, Tulassay Z, Pronai L, Kupcinskas L, Kiudelis G, Pokrotnieks J, Kovács A, Faszczyk M, Razbadauskas A, Margus B, Stolte M, Müller R, Greinwald R; International Budesonide Foam Study Group. Gross V, et al. Among authors: margus b. Aliment Pharmacol Ther. 2006 Jan 15;23(2):303-12. doi: 10.1111/j.1365-2036.2006.02743.x. Aliment Pharmacol Ther. 2006. PMID: 16393311 Clinical Trial.